It is very clear that AMBS has a methodical stepwise plan to get to an uplist and beyond. The puzzle pieces are being assembled. From a strategic perspective, it was very smart to add to the pipeline with an acquisition (ESS) before what looks like a sale or significant transaction related to Lympro. Surprised there was not an actual PR about Dr. Lowe assuming the role of AMBS President, Europe. Still early.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links